Toby Ferguson, M.D., Ph.D., is a distinguished medical professional and scientist who currently serves as the Chief Medical Officer at Voyager Therapeutics Inc. Dr. Ferguson's academic journey is marked by his dual degrees in medicine and philosophy, which he earned from prestigious institutions. His medical degree equipped him with a deep understanding of clinical practice, while his Ph.D. in philosophy honed his critical thinking and ethical reasoning skills. This unique combination of expertise has positioned him as a valuable asset in the biopharmaceutical industry, where he applies his knowledge to advance therapeutic development. Before joining Voyager Therapeutics, Dr. Ferguson held several key positions in both academia and the pharmaceutical sector. He has been involved in numerous clinical trials and research projects, focusing on neurology and neurodegenerative diseases. His work has contributed significantly to the understanding and potential treatment of conditions such as Alzheimer's and Parkinson's disease. At Voyager Therapeutics, Dr. Ferguson leads the clinical development team, overseeing the design and execution of clinical trials for gene therapy programs aimed at treating these debilitating disorders. His role involves ensuring that the company's therapeutic candidates are safe, effective, and meet regulatory standards. Dr. Ferguson's leadership at Voyager Therapeutics is characterized by his commitment to advancing innovative treatments and his ability to navigate the complex landscape of drug development. Under his guidance, the company has made strides in developing novel gene therapies that have the potential to transform the lives of patients suffering from neurodegenerative diseases. His strategic vision and dedication to scientific excellence continue to drive Voyager Therapeutics forward, positioning the company as a leader in the field of gene therapy.